drugset / Trial / NCT01704651
Accelerating Gastrointestinal Recovery
Phase 3
Completed
146 enrolled
Jamie N. Bakkum-Gamez
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study is designed to determine whether an oral perioperative medication (alvimopan--a selective mu antagonist) improves bowel recovery over placebo after surgery for ovarian cancer.
Timeline
- Start
- 2013-01
- Primary completion
- 2015-08
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alvimopan | Small molecule | 12 mg | Oral |